Bayer boosts drug pipeline with Vividion buy, lifts outlook
FILE PHOTO: The logo of Bayer AG is seen in a showroom of the German drugmaker where the annual results news conference takes place in Leverkusen, Germany February 27, 2020. REUTERS/Wolfgang Rattay/File Photo
August 5, 2021
By Christoph Steitz
FRANKFURT (Reuters) -Bayer on Thursday boosted its drug pipeline with a $2 billion takeover and lifted its outlook for 2021 after sales of prescription medicines recovered from restrictions related to the COVID-19 pandemic.
Bayer now expects sales of 43 billion euros ($50.9 billion) this year, up from 41 billion earlier. Core earnings (EBITDA) before special items are seen at 10.6 billion to 10.9 billion euros, compared with 10.5 billion to 10.8 billion previously.
Some of Germany s best-known
brands and industry bellwethers lifted their full-year sales and
profit expectations on Thursday, citing a broad demand recovery
from the effects of the pandemic. . | August 5, 2021
Bayer said on Thursday it was not increasing its $2 billion in provisions after a U.S. judge rejected its class action plan to settle future claims related to its Roundup and other glyphosate-based weedkillers.
Bayer (BAYGn.DE) said on Thursday it was not increasing its $2 billion in provisions after a U.S. judge rejected its class action plan to settle future claims related to its Roundup and other glyphosate-based weedkillers.